Piramal Pharma Limited has announced the successful closure of a US FDA inspection at its manufacturing facility in Digwal, Telangana. The company received the Establishment Inspection Report (EIR), confirming that the regulatory body has finalized the review of the site. This positive development follows a prior disclosure made on February 14, 2026, regarding the site’s inspection status.
Regulatory Milestone at Digwal Site
Piramal Pharma Limited has officially confirmed the successful outcome of the US FDA inspection at its manufacturing unit located in Digwal, Telangana. The receipt of the Establishment Inspection Report (EIR) signifies that the US FDA has formally closed the inspection process for this specific facility.
Context and Significance
This update serves as a conclusion to the inspection process that was initially communicated to stakeholders on February 14, 2026. The successful closure of the audit reinforces the facility’s adherence to quality and compliance standards required for operations within the United States market. The formal intimation of this progress was provided on May 18, 2026, marking a positive development for the company’s manufacturing operations.
Source: BSE
